BRINAVESS 20 MGML 이스라엘 - 영어 - Ministry of Health

brinavess 20 mgml

tzamal bio-pharma ltd - vernakalant hydrochloride - concentrate for solution for infusion - vernakalant hydrochloride 20 mg/ml - vernakalant - vernakalant - rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults who are hemodynamically stable.- for non-surgery patients: atrial fibrillation ≤ 7 days duration- for post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration

Brinavess 유럽 연합 - 영어 - EMA (European Medicines Agency)

brinavess

correvio - vernakalant hydrochloride - atrial fibrillation - cardiac therapy - rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults:for non-surgery patients: atrial fibrillation 

BRINAVESS SOLUTION 캐나다 - 영어 - Health Canada

brinavess solution

cipher pharmaceuticals inc - vernakalant hydrochloride - solution - 20mg - vernakalant hydrochloride 20mg - class iii antiarrythmics

Brinavess 뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

brinavess

merck sharp & dohme (new zealand) limited - vernakalant hydrochloride 20 mg/ml equivalent to 18.1 mg/ml of vernakalant - concentrate for infusion - 20 mg/ml - active: vernakalant hydrochloride 20 mg/ml equivalent to 18.1 mg/ml of vernakalant excipient: citric acid monohydrate sodium chloride sodium hydroxide water for injection - rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults · for non-surgery patients: atrial fibrillation less than or equal to 7 days duration · for post-cardiac surgery patients: atrial fibrillation less than or equal to 3 days duration

BRINAVESS Concentrate for Solution for Infusion 20mg/ml 싱가포르 - 영어 - HSA (Health Sciences Authority)

brinavess concentrate for solution for infusion 20mg/ml

zuellig pharma pte. ltd. - vernakalant 18.1mg/ml equivalent vernakalant hydrochloride - infusion, solution concentrate - 20mg/ml

Namuscla 유럽 연합 - 영어 - EMA (European Medicines Agency)

namuscla

lupin europe gmbh - mexiletine hydrochloride - myotonic disorders - cardiac therapy - namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.

BRINAVESS 200 mg Infusion 남아프리카 - 영어 - South African Health Products Regulatory Authority (SAHPRA)

brinavess 200 mg infusion

pharmacare limited - infusion - each 1,0 ml solution contains vernakalant hydrochloride 20,0 mg

BRINAVESS 500 mg Infusion 남아프리카 - 영어 - South African Health Products Regulatory Authority (SAHPRA)

brinavess 500 mg infusion

pharmacare limited - infusion - each 1,0 ml solution contains vernakalant hydrochloride 20,0 mg